# A Study of Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Treated With Lisocabtagene Maraleucel in the Post-Marketing Setting

> **NCT06788639** · — · RECRUITING · sponsor: **Juno Therapeutics, Inc., a Bristol-Myers Squibb Company** · enrollment: 300 (estimated)

## Conditions studied

- Chronic Lymphocytic Leukemia (CLL)
- Small Lymphocytic Lymphoma (SLL)

## Interventions

- **BIOLOGICAL:** Lisocabtagene maraleucel

## Key facts

- **NCT ID:** NCT06788639
- **Lead sponsor:** Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** RECRUITING
- **Start date:** 2025-02-04
- **Primary completion:** 2044-06-30
- **Final completion:** 2044-06-30
- **Target enrollment:** 300 (ESTIMATED)
- **Last updated:** 2025-02-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06788639

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06788639, "A Study of Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Treated With Lisocabtagene Maraleucel in the Post-Marketing Setting". Retrieved via AI Analytics 2026-07-27 from https://api.ai-analytics.org/clinical/NCT06788639. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*